Manhattan West Asset Management LLC Invests $2.22 Million in Avantor, Inc. $AVTR

Manhattan West Asset Management LLC purchased a new stake in Avantor, Inc. (NYSE:AVTR) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 224,212 shares of the company’s stock, valued at approximately $2,220,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in AVTR. EverSource Wealth Advisors LLC boosted its stake in Avantor by 119.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock worth $29,000 after buying an additional 1,189 shares during the last quarter. Private Trust Co. NA increased its stake in Avantor by 46.2% during the fourth quarter. Private Trust Co. NA now owns 2,769 shares of the company’s stock worth $32,000 after acquiring an additional 875 shares during the last quarter. Strategic Wealth Investment Group LLC purchased a new stake in Avantor in the second quarter valued at $32,000. Los Angeles Capital Management LLC purchased a new stake in Avantor in the fourth quarter valued at $32,000. Finally, Osaic Holdings Inc. lifted its stake in shares of Avantor by 60.9% in the 2nd quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock valued at $38,000 after purchasing an additional 1,064 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Stock Performance

Shares of AVTR stock opened at $14.45 on Friday. The firm has a 50 day moving average of $11.63 and a two-hundred day moving average of $9.65. The stock has a market capitalization of $9.77 billion, a PE ratio of -17.20, a P/E/G ratio of 10.76 and a beta of 0.89. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65. Avantor, Inc. has a 52 week low of $7.26 and a 52 week high of $15.93.

Avantor (NYSE:AVTR) last posted its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.02. The business had revenue of $1.69 billion for the quarter, compared to analyst estimates of $1.61 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The company’s revenue was up .5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, research analysts predict that Avantor, Inc. will post 0.81 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Citigroup increased their price target on Avantor from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Barclays boosted their price objective on shares of Avantor from $7.00 to $8.00 and gave the company an “underweight” rating in a report on Wednesday, June 24th. Zacks Research raised shares of Avantor from a “strong sell” rating to a “hold” rating in a research note on Thursday, April 30th. Wolfe Research upgraded shares of Avantor from a “strong sell” rating to a “hold” rating in a research report on Thursday, July 30th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $13.00 price target on shares of Avantor in a research note on Thursday, July 30th. Two equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $12.00.

Avantor Company Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.